TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/03/2025
Voltar para busca
Dado oficial do USPTO
BICYCLE TUMOR-TARGETED IMMUNE CELL AGONIST
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
BICYCLE TUMOR-TARGETED IMMUNE CELL AGONIST
ST13
US500000079301041Classe
5, 42
Pedido
79301041
Registro
6624273
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
02/04/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
27/10/2020
Data de registro
25/01/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
25/01/2022
Última transação
02/04/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
DAVIS, MARC
Unidade examinadora
N40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Bicycletx Limited
Bicycletx Limited
Representantes
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical productspharmaceutical preparations for use in oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disorders; pharmaceutical preparations for use as diagnosticsdiagnostic preparations for medical use and for use as clinical imaging agents
Classe 42
Scientific and technological services and research and design relating theretoscientific researchnew product design servicesnew study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumorsmetabolic diseaseurology and renal diseasecardiovascularhematologyrespiratorychronic and acute inflammatory disease and auto-immune disordersgastrointestinal diseasebacterial and viral infectious diseaseneurological and psychiatric disordersdiagnostic preparations and clinical imaging agents; informationconsultancy and advisory services relating to the aforesaid
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
26/03/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/03/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/03/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/03/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/03/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/12/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
24/09/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/08/2022
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/07/2022
XXCR
GENERIC MADRID TRANSACTION CREATED
02/07/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
25/04/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
25/01/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/11/2021
PUBO
PUBLISHED FOR OPPOSITION
09/11/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/10/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/09/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/09/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/09/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
21/09/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
21/09/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
21/09/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
21/09/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
21/09/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
17/09/2021
RFNT
REFUSAL PROCESSED BY IB
25/04/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/04/2021
RFRR
REFUSAL PROCESSED BY MPU
05/04/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/03/2021
CNRT
NON-FINAL ACTION WRITTEN
29/03/2021
DOCK
ASSIGNED TO EXAMINER
28/03/2021
MAFR
APPLICATION FILING RECEIPT MAILED
06/01/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/01/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
31/12/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BICYCLE TUMOR-TARGETED IMMUNE CELL AGONIST ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.